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Don’t let the devil ride 
Oh, don’t you let the devil ride 
If you let the devil ride, he’ll wanna drive 
Don’t let him ride 
Don’t you let him flag you down 
Oh, don’t you let him flag you down 
If he flags you down, he’ll turn your soul around 
Don’t let him ride 
Don’t you let him be your boss 
Oh, don’t you let him be your boss 
 
        †   Kurt R. Karst is a Director at the Washington, D.C. law firm Hyman, 
Phelps & McNamara, P.C. The views expressed in this article are the views of the 
author and do not necessarily represent the views of Hyman, Phelps & McNamara, 
P.C. or any of its clients. 
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If you let him be your boss, your soul will be lost 
Don’t let him ride 
Don’t let him drive your car 
Oh, don’t you let him drive your car 
If you let him drive your car, he’ll surely go too far 
Don’t let him drive 
I. INTRODUCTION 
These lyrics from an unknown author of the gospel song Don’t 
Let the Devil Ride tell the story of the consequences of allowing the 
devil to take over one’s life by giving into temptation once too 
often; by crossing the proverbial line in the sand. The lyrics also 
provide a nice characterization of the Food and Drug Adminis-
tration’s (FDA or “Agency”) nearly thirty years of responding to 
citizen petitions requesting permission to submit an Abbreviated 
New Drug Application (ANDA) for a proposed drug product that 
deviates in some respect from the brand-name Reference Listed 
Drug (RLD) relied on for approval—the so-called “petitioned 
ANDA.” 
Submitted pursuant to section 505(j)(2)(C)1 of the Federal 
Food, Drug, and Cosmetic Act (FDC Act),2 as amended by the Drug 
Price Competition and Patent Term Restoration Act of 1984,3 
which is more commonly known as the Hatch-Waxman Act, the 
petitioned ANDA was, for several years, a mainstay of the generic 
drug industry’s drug development paradigm.4 Although the 
popularity of the petitioned ANDA has waned in recent years, it 
remains a viable route for many generic drug applicants to obtain 
approval of a drug product without having to conduct expensive 
and time-consuming clinical studies. However, the continued 
success—and reinvigoration—of the petitioned ANDA depends in 
large part on the FDA’s ability to promptly review and act on ANDA 
suitability petitions within the statutory ninety-day period. 
 
 1.  Federal Food, Drug, and Cosmetic (FDC) Act § 505(j)(2)(C), 21 U.S.C. 
§ 355(j)(2)(C) (2012). 
 2.  21 U.S.C. §§ 301–399f. 
 3.  Pub. L. No. 98-417, 98 Stat. 1585 (1984) (codified as amended in 
scattered sections of 21 and 35 U.S.C.). 
 4.  A similar provision applicable to generic animal drugs was enacted as 
part of the Generic Animal Drug and Patent Term Restoration Act, Pub. L. 
No. 100-670, 102 Stat. 3971 (1988). See also FDC Act § 512(n)(3), 21 U.S.C. 
§ 360b(n)(3).  
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This article provides the first ever analysis of the FDA’s nearly 
thirty-year track record of responding to ANDA suitability petitions 
submitted pursuant to FDC Act section 505(j)(2)(C). Part II traces 
the history of generic drug development and the petitioned ANDA 
from a regulation promulgated shortly before the enactment of the 
Hatch-Waxman Act on September 24, 1984, to the current statute.5 
Part III analyzes almost 1300 suitability petitions submitted to the 
FDA since September 24, 1984, and provides various data tables on 
the number of suitability petitions submitted to and acted on by the 
FDA each year from 1984 to 2013, including the annual average 
and median timeframes from petition submission to an FDA 
decision.6 Part IV suggests some reasons for the decline in the 
popularity of the petitioned ANDA as a vehicle for obtaining 
approval of a generic drug.7 Finally, Part V recommends that the 
FDA implement procedures to meet the statutory ninety-day 
deadline for approving or disapproving an ANDA suitability 
petition, or that Congress amend the FDC Act to provide the FDA 
with a more practical deadline to rule on a suitability petition.8 
II. A HISTORICAL ACCOUNT OF THE “PETITIONED ANDA” 
The ANDA suitability petition provisions of the FDC Act are 
short and total slightly more than 150 words: 
If a person wants to submit an abbreviated application for 
a new drug which has a different active ingredient or 
whose route of administration, dosage form, or strength 
differ from that of a listed drug, such person shall submit 
a petition to the Secretary seeking permission to file such 
an application. The Secretary shall approve or disapprove 
a petition submitted under this subparagraph within 
ninety days of the date the petition is submitted. The 
Secretary shall approve such a petition unless the 
Secretary finds— 
(i) that investigations must be conducted to show the 
safety and effectiveness of the drug or of any of its 
active ingredients, the route of administration, the 
dosage form, or strength which differ from the listed 
drug; or 
 
 5.  See infra Part II. 
 6.  See infra Part III. 
 7.  See infra Part IV. 
 8.  See infra Part V. 
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(ii) that any drug with a different active ingredient 
may not be adequately evaluated for approval as safe 
and effective on the basis of the information required 
to be submitted in an abbreviated application.9 
Although the statutory text for the petitioned ANDA is short, 
the historical context in which the petitioned ANDA was created 
and developed is not. A broader understanding of the historical 
milieu leading up to the enactment of the Hatch-Waxman Act, and 
the provisions of that Act governing generic drug approval, are 
necessary to understand the development of the petitioned ANDA. 
A. The Hatch-Waxman Regulatory Pathway 
The first generic drugs10 were those marketed during the 
period between the enactment of the FDC Act in 193811 and the 
enactment of the Drug Amendments of 196212 without FDA 
approval, on the theory that the FDA’s approval of the brand-name 
drug (also referred to as a pioneer drug) under a New Drug 
Application (NDA) based only on safety made the next version an 
“old” drug.13 In the period after 1962, the FDA required the 
 
 9.  FDC Act § 505(j)(2)(C), 21 U.S.C. § 355(j)(2)(C). 
 10.  The term “generic drug” is not defined in the FDC Act or in the FDA’s 
regulations. It is used, however, generally to refer to a drug product with the same 
active ingredient as a brand-name drug. 
 11.  FDC Act, ch. 675, 52 Stat. 1040 (1938). 
 12.  Pub. L. No. 87-781, 76 Stat. 780.  
 13.  The 1962 Drug Amendments also required the FDA to evaluate the 
effectiveness of drug products approved as safe between June 25, 1938, and 
October 10, 1962. The FDA engaged the National Academy of Science/National 
Research Council (NAS/NRC) to evaluate the effectiveness of the more than 3400 
products approved based upon safety. The NAS/NRC review was broken down 
into specific drug categories. Review results were submitted to the FDA, which 
then reviewed and reevaluated the NAS/NRC findings and published its own 
findings in the Federal Register. The FDA’s administrative implementation of the 
NAS/NRC reports is called the Drug Efficacy Study Implementation (DESI) 
program. DESI covered the products specifically reviewed by the NAS/NRC, as 
well as the even larger number of Identical, Related, or Similar (IRS) products 
that had entered the market without FDA approval. See 21 C.F.R. § 310.6(b)(1) 
(2009) (defining “IRS” drugs). If the FDA’s final determination classified a drug as 
effective for its labeled indications, the Agency frequently required sponsors of 
approved NDAs (referred to as “deemed approved” NDAs) to supplement their 
applications for continued marketing of the drug, and sponsors of IRS drugs to 
submit ANDAs seeking approval. If the FDA’s final determination classified a drug 
as ineffective, then, because DESI products were covered by “deemed approved” 
4
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submission of an ANDA for each generic drug, but did not permit 
ANDAs to be submitted for brand-name drugs approved after 
1962.14 This meant that a second version of a post-1962 brand-name 
drug had to obtain full NDA approval. A full NDA was economically 
prohibitive. 
Competitive pressure drove some generic drug companies to 
market both pre- and post-1962 drugs without FDA approval, 
arguing that an active ingredient became available as an “old” drug 
after initial FDA approval. The FDA’s attempts to suppress this 
practice culminated in the 1983 Supreme Court decision United 
States v. Generix Drug Corp.15 The Court accepted the FDA’s position 
that “old drug” status applied not to the active ingredient, but to 
the individual finished product. Hence, each new version of a drug 
was a “new drug”16 requiring FDA approval no matter how many 
times the FDA had approved its active ingredient.17 
Aware that the Agency’s own policies and interpretations were 
preventing generic competition for post-1962 drugs, the FDA took 
two steps: (1) the development of the so-called “paper NDA” policy 
and (2) the development of ANDA regulations for post-1962 drug 
products. In 1978, the FDA adopted the “paper NDA” policy, under 
which the Agency accepted a combination of product-specific data 
and published literature about an active ingredient in satisfaction 
of the approval requirements for a full NDA.18 The FDA’s “paper 
 
NDAs, the Agency was required to follow administrative hearing procedures to 
withdraw the NDA.  
 14.  See 35 Fed. Reg. 6574 (Apr. 24, 1970).  
 15.  460 U.S. 453 (1983). 
 16.  A product that is a “new drug” within the meaning of FDC Act section 
201(p) may not be introduced into interstate commerce unless there is an 
approved marketing application (e.g., an NDA), or unless an exemption has been 
granted permitting the introduction of the drug into interstate commerce (e.g., 
an effective Investigational NDA). 
 17.  Over-the-counter drug products marketed pursuant to a monograph are 
an exception to this rule. See 21 C.F.R. pt. 330 (2013). 
 18.  See NDAs for Duplicate Drug Products of Post-1962 Drugs, 46 Fed. 
Reg. 27,396 (May 19, 1981). The “paper NDA” policy is described in a July 31, 
1978 FDA staff memorandum. The policy was not originally published in the 
Federal Register because the FDA determined that rulemaking procedures were not 
required because “the policy is a lawful exercise of [the] FDA’s statutory authority” 
45 Fed. Reg. 82,052 (Dec. 12, 1980). The FDA was challenged on this issue in 
court and won. See Burroughs Wellcome Co. v. Schweiker, 649 F.2d 221, 225 (4th 
Cir. 1981). Subsequently, in separate litigation, the United States District Court for 
the Northern District of Illinois ruled that upon publication of the FDA’s policy in 
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NDA” policy essentially permitted the sponsor of an application for 
a “duplicate” of a post-1962 drug product (i.e., a drug product that 
contained the same active ingredients as an already marketed 
product, in a similar or identical dosage form, and for the same 
indications) to submit published studies and “bridging” data in 
support of its application.19 However, because the “paper NDA” 
approach required published literature rather than information 
not publicly available, it had limited utility for most drugs.20 
In 1978, the FDA also issued proposed regulations in which 
the Agency expressed its intent to extend its pre-1962 ANDA 
regulations to post-1962 drugs.21 The FDA began to develop these 
regulations in the early 1980s, but never published them. The 
FDA’s initiative was controversial because it reportedly would have 
required a substantial waiting period after initial approval of the 
brand-name drug before any ANDA could be approved for a 
generic version. Congressional interest in the FDA’s initiative, 
however, coincided with a broader effort to develop legislation that 
would promote both competition and innovation in the 
pharmaceutical industry.22 
 
the Federal Register, the Agency could implement it without rulemaking procedures. 
See Am. Critical Care v. Schweiker, No. 81-C-252, 1981 Dist. Lexis 12363 (N.D. Ill. 
May 13, 1981). 
 19.  The published studies requirement could be met by referencing data 
available in published literature, laboratory reports, physician evaluation forms, 
and even unpublished reports when available and necessary. However, the 
underlying data did not have to be included or referenced, as was required under 
the FDA’s old interpretation of “full reports” in FDC Act section 505(b)(1). 
Reference to information not publicly available was not permitted, including 
information in the innovator product’s NDA. The “bridging” data requirement 
could be met by submitting data from a bioavailability/bioequivalence study 
comparing the drug that was the subject of the “paper NDA” to the approved drug 
“to show that the drug is comparable in blood levels (or dissolution rate, as 
required) to the innovator’s product.” NDAs for Duplicate Drug Products of Post-
1962 Drugs, 46 Fed. Reg. at 27,397.  
 20.  The FDA revoked the “paper NDA” policy in 1989 when the Agency 
proposed regulations implementing the Hatch-Waxman Act. See Abbreviated New 
Drug Application Regulations, 54 Fed. Reg. 28,872, 28,890 (proposed July 10, 
1989). 
 21.  See Abbreviated New Drug Applications, 43 Fed. Reg. 39,126, 39,128 
(proposed Sept. 1, 1978).  
 22.  See, e.g., Drug Regulation Reform Act, H.R. 2217, 96th Cong. (1979); 
Drug Regulation Reform Act, H.R. 12980, 95th Cong. (1978). 
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The FDA’s extended approval process after 1962 undercut the 
value of drug patents, which are granted early in the development 
process, and much of their then-seventeen-year term from issuance 
(now twenty-year term from filing) was eaten up before the FDA 
granted marketing approval. Congress engineered a compromise 
in which brand-name drug companies could obtain a patent term 
extension and generic drug companies could obtain ANDA 
approval for pre- and post-1962 drugs. The compromise was 
enacted on September 24, 1984, as the Hatch-Waxman Act.23 
The Hatch-Waxman Act resulted from years of legislative effort 
and pharmaceutical industry engagement. The goals of this 
legislation were: (1) to provide a shortened, predicable pathway for 
manufacturers to more quickly market generic versions of brand-
name drugs; (2) to restore some of the patent protection that 
innovator drug developers often lost while their products were 
under FDA review; and (3) to substantially lower the cost to 
consumers of drugs the FDA has determined do not require 
additional safety and effectiveness testing.24 
The Hatch-Waxman Act amended, among other things, the 
new drug approval provisions of the FDC Act to add 
section 505(j).25 Section 505(j) formalized the legal structure for 
generic drugs, under which an ANDA containing bioequivalence 
data to a brand-name drug—i.e., the RLD, which is defined as “the 
listed drug identified by [the] FDA as the drug product upon which 
an applicant relies in seeking approval of its abbreviated 
application”26—among other data and information, was sufficient 
for the FDA to consider approval. The Hatch-Waxman Act also 
amended the new drug approval provisions of the FDC Act to add 
section 505(b)(2) in an attempt to codify the FDA’s “paper NDA” 
policy27 and the patent laws to authorize a patent term extension 
 
 23.  Pub. L. No. 98-417, 98 Stat. 1585 (1984) (codified as amended in 
scattered sections of 21 and 35 U.S.C.). 
 24.  See H.R. REP. NO. 98-857, pt. 2, at 14 (1984), reprinted in 1984 
U.S.C.C.A.N. 2686, 2698.  
 25.  21 U.S.C. § 355(j) (2012). 
 26.  21 C.F.R. § 314.3(b) (2013).  
 27.  A section 505(b)(2) application differs from a “paper NDA” in that it 
permits the sponsor of a drug that may differ substantially from a drug listed in the 
FDA’s Orange Book to rely on the FDA’s determination of the safety and 
effectiveness of a listed drug and/or on published studies or studies in an NDA (or 
NDAs) sponsored by another person, together with studies generated on its own 
drug product, as a way to satisfy the requirement of “full reports” of safety and 
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for time lost during the regulatory review period28 and to permit a 
safe harbor for generic drug companies to perform research and 
tests in preparation of regulatory approval.29 
The premise of FDC Act section 505(j) is that an ANDA drug is 
the “same as” the brand-name RLD. However, differences are 
allowed in route of administration, dosage form, and strength, as 
well as in an active ingredient in a combination drug product. 
Those differences must first be approved by the FDA under 
a suitability petition as not requiring clinical investigations.30 
Section 505(j)(2)(A)31 states that an ANDA that is not the subject of 
an approved suitability petition must contain information to show, 
among other things, that the active ingredient, “the route of 
administration, the dosage form, and the strength of the new drug 
are the same as those of the [RLD].”32 
An ANDA must contain, among other things identified in the 
FDC Act and in the FDA’s ANDA format and content regulations,33 
information demonstrating that the generic version is 
bioequivalent to the RLD.34 This information may come from in 
vivo (human) and/or in vitro (test tube) studies.35 The purpose of 
demonstrating bioequivalence is to determine whether a proposed 
drug product’s formulation or manufacturing affect the rate or 
extent to which the active ingredient reaches the primary site of 
action. Although data and information demonstrating in vivo 
bioequivalence is often required, the FDA may waive this 
requirement if in vivo bioequivalence is considered self-evident, or 
for other reasons.36 
 
effectiveness. As with the old “paper NDA” policy, “bridging” studies to the listed 
drug are necessary. An application that is for a duplicate of a drug listed in the 
Orange Book and eligible for approval under FDC Act section 505(j) may not be 
submitted as a section 505(b)(2) application. 
 28.  See 35 U.S.C. § 156 (2006). 
 29.  See id. § 271(e)(1). 
 30.  See FDC Act § 505(j)(2)(C), 21 U.S.C. § 355(j)(2)(C); 21 C.F.R. § 314.93. 
 31.  21 U.S.C. § 355(j)(2)(A) (2012). 
 32.  FDC Act § 505(j)(2)(A)(iii), 21 U.S.C. § 355(j)(2)(A)(iii). 
 33.  See generally 21 C.F.R. § 314.94. 
 34.  See FDC Act § 505(j)(2)(A)(iv), 21 U.S.C. § 355(j)(2)(A)(iv). The term 
“bioequivalence” is defined in the FDC Act and the FDA’s regulations. See FDC Act 
§ 505(j)(8)(B), 21 U.S.C. § 355(j)(8)(B); 21 C.F.R. § 320.1(e).  
 35.  See generally 21 C.F.R. § 320. 
 36.  See id. § 320.22. 
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Under the FDC Act, ANDA approval is subject to several 
restrictions. First, the Hatch-Waxman Act included nonpatent 
marketing exclusivity provisions of three or five years to 
compensate brand-name drug companies for allowing reliance on 
their proprietary research.37 Second, as explained below, an ANDA 
applicant must notify an NDA holder and patent owner if a patent 
listed in the FDA’s Approved Drug Products with Therapeutic 
Equivalence Evaluations (commonly referred to as the “Orange 
Book” because of its orange cover) claims the RLD; if the NDA 
owner timely files a patent infringement suit, approval of the 
ANDA could be delayed. Third, an ANDA drug product must 
contain the “same” active ingredient as the brand-name drug and 
have essentially the same labeling, including indications, warnings, 
contraindications, etc. 
The FDC Act and FDA regulations require each NDA sponsor 
to submit with its application 
the patent number and the expiration date of any patent 
which claims the drug for which the applicant submitted 
the [NDA] or which claims a method of using such drug 
and with respect to which a claim of patent infringement 
could reasonably be asserted if a person not licensed by 
the owner engaged in the manufacture, use, or sale of the 
drug.38 
FDA regulations clarify that “such patents consist of drug 
substance (active ingredient) patents, drug product (formulation 
and composition) patents, and method-of-use patents.”39 Thus, in 
order to list a patent in the Orange Book: (1) the patent must 
claim the drug or a method of using the drug that is the subject of 
the NDA; and (2) a claim of patent infringement could reasonably 
be asserted by the NDA holder or patent owner for the 
unauthorized manufacture, use, or sale of the drug that is the 
subject of the NDA.40 
 
 37.  See FDC Act § 505(c)(3)(E)(j)(5)(F), 21 U.S.C. § 355(c)(3)(E)(j)(5)(F). 
 38.  FDC Act § 505(b)(1), 21 U.S.C. § 355(b)(1). 
 39.  21 C.F.R. § 314.53(b)(1). 
 40.  See Applications for FDA Approval to Market a New Drug: Patent 
Submission and Listing Requirements and Application of 30-Month Stays on 
Approval of Abbreviated New Drug Applications Certifying That a Patent Claiming 
a Drug Is Invalid or Will Not Be Infringed, 68 Fed. Reg. 36,676 (June 18, 2003) 
(codified at 21 C.F.R. pt. 314). 
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Once an NDA is approved, the FDA is required to publish 
information in the Orange Book on the patents claiming the drug 
or a method of using it.41 If a new patent meeting the requirements 
of FDC Act § 505(b)(1) and the FDA’s patent listing regulations is 
issued while an NDA is pending FDA review or after NDA approval, 
the NDA sponsor is required to submit information on the patent 
to the FDA within thirty days of issuance.42 
An ANDA for a generic version of an innovator drug must 
contain one of four possible certifications “with respect to each 
patent which claims the [innovator] drug . . . or which claims a use 
for such listed drug . . . and for which information is required to be 
filed” by the NDA holder which is listed in the Orange Book.43 If 
there are patents on the drug, and the ANDA applicant does not 
want to challenge one or more of them, then the applicant submits 
a “Paragraph III” certification to each patent it does not want to 
challenge, and the FDA cannot approve the application until the 
patents have expired.44 If a patent has already expired, or if the 
required patent information has not been filed, then the ANDA 
applicant submits a “Paragraph II” or “Paragraph I” certification, 
respectively.45 If the ANDA applicant wants to challenge a patent 
listed in the Orange Book, then the applicant submits a “Paragraph 
IV” certification, claiming that the “patent is invalid or will not be 
infringed by the manufacture, use, or sale of the new drug for 
which the [ANDA] is submitted.”46 
As an alternative to these four certifications, if the listed drug 
is covered by an Orange Book–listed “method of use patent which 
does not claim a use for which the [ANDA] applicant is seeking 
approval,” then the application must contain “a statement that the 
method of use patent does not claim such a use.”47 This is often 
referred to as a “section viii statement” and it permits a generic 
applicant to “carve out” of its proposed labeling a patent-protected 
 
 41.  See FDC Act § 505(b)(1), (c)(2), 21 U.S.C. § 355(b)(1), (c)(2).  
 42.  See FDC Act § 505(c)(2), 21 U.S.C. § 355(c)(2); see also 21 C.F.R. 
§ 314.53(c)(2)(ii), (d)(1) and (d)(3). 
 43.  FDC Act § 505(j)(2)(A)(vii), 21 U.S.C. § 355(j)(2)(A)(vii).  
 44.  See FDC Act § 505(j)(2)(A)(vii)(III), (j)(5)(B)(ii), 21 U.S.C. § 355(j)(2) 
(A)(vii)(III), (j)(5)(B)(ii).  
 45.  See FDC Act § 505(j)(2)(A)(vii)(I)–(II), (j)(5)(B)(i), 21 U.S.C. § 355(j) 
(2)(A)(vii)(I)–(II), (j)(5)(B)(i).  
 46.  FDC Act § 505(j)(2)(A)(vii)(IV), (j)(5)(B)(iii), 21 U.S.C. § 355(j)(2) 
(A)(vii)(IV), (j)(5)(B)(iii).  
 47.  FDC Act § 505(j)(2)(A)(viii), 21 U.S.C. § 355(j)(2)(A)(viii).  
10
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use, provided that the omission of such protected information does 
not “render the proposed drug product less safe or effective than 
the listed drug for all remaining, nonprotected conditions of use.”48 
A generic applicant making a Paragraph IV certification must 
notify the NDA holder and patent owner that an application has 
been submitted to the FDA, once the Agency determines that the 
ANDA is substantially complete. The notice must include a 
“detailed statement of the factual and legal basis of the opinion of 
the applicant that the patent is invalid or will not be infringed,” 
and must “state that an application . . . has been submitted . . . for 
the drug with respect to which the certification is made to obtain 
approval to engage in the commercial manufacture, use, or sale of 
the drug before the expiration of the patent referred to in the 
certification.”49 
The NDA holder or patent owner has forty-five days from the 
date of receipt of such notice to file a suit for patent 
infringement.50 If a patent infringement suit is brought by the NDA 
holder or the patent owner within the forty-five day period, then 
the FDA cannot approve the ANDA until the earlier of: (1) the 
expiration of a single thirty-month stay of approval, which may be 
shortened or lengthened by the court if “either party to the action 
fail[s] to reasonably cooperate in expediting the action”;51 (2) the 
date on which a district court enters judgment in favor of the 
defendant (i.e., the ANDA applicant) that the patent is invalid or 
not infringed (or on the date of a settlement order or consent 
decree signed and entered by the court stating that the patent that 
is the subject of the certification is invalid or not infringed);52 
 
 48.  21 C.F.R. § 314.127(a)(7) (2013). An ANDA applicant must make an 
additional certification (or submit an additional “section viii statement”) as to any 
new patent listed in the Orange Book while its application is pending if the NDA 
holder submits the new patent to the FDA for Orange Book listing within thirty 
days of patent issuance. See id. § 314.94(a)(12)(vi). Post-MMA, a Paragraph IV 
certification to a later-listed patent will not result in an additional thirty-month stay 
of ANDA approval. See FDC Act § 505(c)(2), 21 U.S.C. § 355(c)(2); see also 
21 C.F.R. § 314.53(c)(2)(ii). 
 49.  FDC Act § 505(j)(2)(B)(ii), 21 U.S.C. § 355(j)(2)(B)(ii). 
 50.  See FDC Act § 505(j)(5)(B)(iii), 21 U.S.C. § 355(j)(5)(B)(iii).  
 51.  Id. 
 52. The statutory language regarding settlement orders and consent 
decrees was added post-MMA. Compare FDC Act § 505(j)(5)(B)(iii), 21 U.S.C. 
§ 355(j)(5)(B)(iii) (2002), with FDC Act § 505(j)(5)(B)(iii), 21 U.S.C. § 355(j) 
(5)(B)(iii) (2012). 
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or (3) if the district court enters judgment in favor of the plaintiff 
(i.e., the NDA holder or patent owner) and that decision is 
appealed by the ANDA applicant, the date on which the court of 
appeals enters judgment in favor of the ANDA applicant that the 
patent is invalid or not infringed (or on the date of a settlement 
order or consent decree signed and entered by the court of appeals 
stating that the patent that is the subject of the certification is 
invalid or not infringed).53 
If the judgment of the district court is not appealed or is 
affirmed by the court of appeals, then the approval will be made 
effective on the date specified by the district court in a court 
order.54 If a patent infringement suit is not brought by the NDA 
holder or the patent owner within the forty-five-day period, then 
the FDA can approve the ANDA at any time.55 
The Hatch-Waxman Act established an incentive for generic 
manufacturers to submit Paragraph IV certifications and to 
challenge Orange Book–listed patents as invalid or not infringed, 
by providing for a 180-day period of marketing exclusivity.56 This 
means, in certain circumstances, an applicant who submits the first 
ANDA containing a Paragraph IV certification to an Orange Book–
listed patent is protected from competition from other generic 
versions of the same drug product for 180 days. Prior to the 
December 2003 enactment of the Medicare Prescription Drug, 
Improvement, and Modernization Act of 2003 (MMA),57 180-day 
exclusivity was patent-based, such that a period of 180-day 
exclusivity could arise from each Orange Book–listed patent. Pre-
MMA, 180-day exclusivity began on (i.e., was triggered by) the 
earlier of the date the FDA “receive[d] notice from the 
applicant . . . of the first commercial marketing of the drug” under 
the first ANDA or “the date of a decision of a court in [a patent 
infringement action] holding the patent which is the subject of the 
certification to be invalid or not infringed.”58 
 
 53. FDC Act § 505(j)(5)(B)(iii)(II)(aa), 21 U.S.C. § 355(j)(5)(B)(iii)(II)(aa) 
(2012).  
 54.  FDC Act § 505(j)(5)(B)(iii)(II)(bb), 21 U.S.C. § 355(j)(5)(B)(iii)(II) 
(bb). 
 55.  FDC Act § 505(j)(5)(B)(iii), 21 U.S.C. § 355(j)(5)(B)(iii). 
 56.  See Abbreviated New Drug Application Regulations, 54 Fed. Reg. 28,894 
(proposed July 10, 1989). 
 57.  Pub. L. No. 108-173, 117 Stat. 2066 (2003). 
 58.  FDC Act § 505(j)(5)(B)(iv), 21 U.S.C. § 355(j)(5)(B)(iv)(I) (2000). 
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Post-MMA, 180-day exclusivity is generally product-based, such 
that there is a single 180-day exclusivity period with respect to each 
listed drug. Only a “first applicant”—“an applicant that, on the first 
day on which a substantially complete application containing a 
[Paragraph IV Certification] is submitted for approval of a drug, 
submits a substantially complete application that contains and 
lawfully maintains a [Paragraph IV Certification] for the drug”—
can qualify for 180-day exclusivity.59 Post-MMA, there is only a single 
trigger to 180-day exclusivity: first commercial marketing. A first 
applicant that qualifies for 180-day exclusivity can forfeit eligibility 
for such exclusivity under various circumstances.60 
An ANDA subject to an approved suitability petition is treated 
like any conventional ANDA not requiring the approval of a 
suitability petition submitted pursuant to section 505(j) of the FDC 
Act. That is, an ANDA subject to an approved suitability petition 
must contain a certification to each Orange Book–listed patent 
covering the RLD, is subject to a thirty-month stay of approval, and 
is eligible for a period of 180-day exclusivity vis-à-vis subsequent 
Paragraph IV ANDA filers for the same drug product approved 
under the applicable suitability petition.61 
Once the FDA approves an ANDA, information about the drug 
product is added to the FDA’s Orange Book, including whether or 
not the approved generic drug is considered a “therapeutic 
equivalent” to, and thus substitutable for, the brand-name RLD 
relied on for approval. The term “therapeutic equivalence” is not 
defined in the FDC Act or in FDA ANDA regulations; however, 
“[d]rug products are considered to be therapeutic equivalents only 
if they are pharmaceutical equivalents and if they can be expected to 
have the same clinical effect and safety profile when administered 
 
 59.  FDC Act § 505(j)(5)(B)(iv)(II)(bb), 21 U.S.C. § 355(j)(5)(B)(iv)(II)(bb) 
(2012). 
 60.  See generally FDC Act § 505(j)(5)(D)(i)(I)–(VI), 21 U.S.C. § 355(j)(5) 
(D)(i)(I)–(VI) (2012) (listing failure to market the drug within a specified 
timeframe, withdrawing the application, amending or withdrawing patent 
certification, failing to obtain tentative approval, entering an agreement with 
another applicant, and expiration of patent). 
 61.  See, e.g., FOOD & DRUG ADMIN., ANDA 76-642/S-005, S-006, S-007 and 
S-008, LETTER (Oct. 19, 2007) (Hydrocodone Bitartrate and Ibuprofen Tablets, 
2.5 mg/200 mg (new strength)); FOOD & DRUG ADMIN., ANDA 77-660, LETTER 
(July 31, 2007) (Escitalopram Oxalate Capsules, 5 mg (base), 10 mg (base) and 
20 mg (base) (new dosage form)). 
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to patients under the conditions specified in the labeling” (i.e., bio-
equivalent).62 
FDA regulations define the term “pharmaceutical equivalents” 
to mean “drug products in identical dosage forms that contain 
identical amounts of the identical active drug ingredient . . . that 
deliver identical amounts of the active drug ingredient over the 
identical dosing period.”63 Because therapeutic equivalence 
requires that two drug products be pharmaceutically equivalent in 
order to be substitutable, “pharmaceutical alternatives” are not 
therapeutic equivalents and are not substitutable for the RLD 
relied on for approval. Pharmaceutical alternatives are “drug 
products that contain the identical therapeutic moiety, or its 
precursor, but not necessarily in the same amount or dosage form 
or as the same salt or ester.”64 Thus, products approved pursuant to 
an approved suitability petition are pharmaceutical alternatives and 
are not listed in the Orange Book as therapeutically equivalent to, 
and substitutable for, the RLD. 
B. The Development of the Petitioned ANDA 
As discussed above, even before the enactment of the Hatch-
Waxman Act in 1984, the FDA had already created by regulation 
and under Agency policy approval processes for generic drugs: 
ANDAs for generic version of drug products approved under NDAs 
prior to 1962, and “paper NDAs” for versions of drug products 
approved post-1962 under an NDA. It was in this milieu that the 
petitioned ANDA was also created. 
In 1978, the FDA proposed regulations to limit the availability 
of the then-existing ANDA procedures, generally, to drug products 
approved under an NDA between 1938 and 1962 subject to a Drug 
Efficacy Study Implementation (DESI) program finding if the 
proposed generic version was the same as (i.e., identical to) the 
NDA-approved drug product in terms of dosage form, strength, 
 
 62.  FOOD & DRUG ADMIN., APPROVED DRUG PRODUCTS WITH THERAPEUTIC 
EQUIVALENTS, at vii (34th ed. 2014) (emphasis added) (commonly known as “The 
Orange Book”). “[The] FDA believes that products classified as therapeutically 
equivalent can be substituted with the full expectation that the substituted product 
will produce the same clinical effect and safety profile as the prescribed product.” 
Id. 
 63.  21 C.F.R. § 320.1(c) (2013).  
 64.  Id. § 320.1(d).  
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route of administration, active ingredient, and conditions of use.65 
Specifically, the FDA proposed to amend the Agency’s new drug 
regulations to provide: 
A finding by the Commissioner of Food and Drugs that an 
[ANDA] is appropriate for a drug product is limited to 
products that are the same in dosage form, route of 
administration, kind and amount of active ingredient, 
indication(s), and any other conditions of use as the drug 
product that was the subject of the finding. A deter-
mination that an [ANDA] is the appropriate form of 
application for a drug product does not apply to a similar 
or related drug product unless the notice of that finding 
specifies that it applies to a particular similar or related 
product and that product is described.66 
This limitation on the availability of the ANDA procedures was 
necessary because, according to the FDA, “applicants continue to 
submit ANDA’s [sic] for products clearly not subject to the finding 
in a DESI notice that an ANDA is appropriate.”67 As the FDA 
further explained, the Agency’s findings of safety and effectiveness 
for an NDA-approved drug are generally drug-product specific. A 
change, such as a different strength or route of administration, 
“may affect the safety or the effectiveness of the related product or 
at least raise a question about safety or effectiveness that cannot be 
answered without additional data.”68 
To reach a conclusion on whether the FDA’s previous finding 
of safety and effectiveness could extend to a nonidentical version of 
the NDA-approved drug, the FDA proposed the creation of an 
administrative procedure, allowing prospective ANDA applicants to 
petition the FDA pursuant to the Agency’s citizen petition 
procedures at 21 C.F.R. § 10.30 to submit an ANDA for a drug 
product similar or related to an NDA-approved drug product.69 The 
FDA’s proposal was finalized in January 198370 and heralded in the 
era of the ANDA suitability petition. Under the FDA’s final rule, 
the Agency would accept an ANDA “only if it has made a finding 
that an abbreviated application is suitable for the drug product.”71 
 
 65.  See 43 Fed. Reg. 39,126 (proposed Sept. 1, 1978).  
 66.  Id. at 39,129. 
 67.  Id. at 39,128. 
 68.  Id. at 39,127. 
 69.  See id. 
 70.  See 48 Fed. Reg. 2751 (Jan. 21, 1983). 
 71.  21 C.F.R. § 314.2(b)(1) (1984). 
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An FDA finding that an ANDA “is suitable for a drug product . . . 
that is the same in active ingredient, dosage form and strength, 
route of administration, and conditions of use as the drug product 
that was the subject of the finding.”72 “For a drug product that was 
similar but different in one or more of these characteristics,” 
however, the FDA regulation provided that “an [ANDA] will be 
accepted [for review] only if [FDA] has made a separate finding of 
suitability.”73 As the regulation further explained: 
A prospective applicant may seek a determination of the 
suitability of an [ANDA] for a product that the applicant 
believes similar or related to a drug product that has been 
declared to be suitable for an [ANDA]. Extension of the 
finding that a drug product is safe and effective to 
another product will ordinarily be limited to other dosage 
forms for the same route of administration or to closely 
related ingredients. If preclinical or clinical evidence is 
needed to support the safety, or if clinical evidence is 
needed to support the effectiveness, of the proposed 
product, then an [ANDA] is not suitable for the similar or 
related drug product.74 
To obtain an FDA finding of ANDA suitability, the Agency 
instructed prospective applicants to submit a citizen petition in 
which “[t]he petitioner shall set forth the reasons that justify 
extending the finding that an [ANDA] is suitable for one product 
to the similar or related product proposed to be marketed.”75 The 
FDA also required each ANDA submitted to the Agency “to contain 
a reference to the finding of the [FDA] that an abbreviated 
application is suitable for the specific product that is the subject of 
the application.”76 Notwithstanding the detailed nature of the 
 
 72.  Id. § 314.2(b)(2). 
 73.  Id.  
 74.  Id. § 314.2(c). 
 75.  Id. § 314.2(d). The regulation further provides that “[a] new drug 
application submitted in the form of an [ANDA] for a drug product that has not 
been the subject of a finding that allows an abbreviated application for the 
product will be considered to be a petition under § 10.30 of this chapter and will 
be processed as such.” Id. § 314.2(e). 
 76.  Id. § 314.2(f). In 1985, the FDA completed a revision and reorganized 
certain of the Agency’s regulations and moved § 314.2 to 21 C.F.R. § 314.55. 
See New Drug and Antibiotic Regulations, 50 Fed. Reg. 7452, 7466 (Feb. 22, 1985). 
Section 314.55 was removed in 1992 with the promulgation of final regulations 
implementing the ANDA provisions of the Hatch-Waxman Amendments. 
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FDA’s final rule, it did not specify any timeframe or deadline for 
the FDA to approve or disapprove a suitability petition. 
Slightly more than a year and nine months after the FDA 
promulgated its ANDA suitability petition regulations, the Hatch-
Waxman Act was enacted and created the contemporary ANDA 
procedures applicable to generic versions of all FDA-approved 
drugs. Among other things, the Hatch-Waxman Act effectively 
codified the suitability petition procedures that the FDA had 
promulgated.77 
In creating the ANDA suitability petition process, Congress 
noted that four types of changes are permitted to be made by a 
suitability petition—a change in dosage form, strength, route of 
administration, or, in the case of a combination drug product, a 
change in one active ingredient—and that these are “the only 
changes from the listed drug for which an applicant may petition 
[the FDA].”78 Congress also, however, wisely added a requirement 
that the FDA timely rule on ANDA suitability petitions. Under the 
statute, the FDA “shall approve or disapprove a petition . . . within 
ninety days of the date the petition is submitted” to the Agency.79 
The FDA issued proposed regulations in 1989 to implement 
the Hatch-Waxman Act,80 and finalized those regulations regarding 
ANDA submission and approval in 1992.81 The regulations 
concerning ANDA suitability petitions, which are located at 
21 C.F.R. § 314.93, were finalized with relatively little opposition.82 
The regulations detail the content and format of a suitability 
petition,83 the conditions under which the FDA will approve or 
 
See Abbreviated New Drug Application Regulations, 57 Fed. Reg. 17,950, 17,983 
(Apr. 28, 1992). 
 77.  Hatch-Waxman Act, Pub. L. No. 98-417, 98 Stat. 1585, 1587 (1984) 
(codified as amended at 21 U.S.C. § 355(j)(2)(C) (2012)). 
 78.  H.R. REP. NO. 98-857, pt. 1, at 23 (1984), reprinted in 1984 U.S.C.C.A.N. 
2647, 2656. As an alternative to submitting an ANDA subject to an approved 
suitability petition for these types of changes, a company may instead submit a 
section 505(b)(2) application. See FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR 
INDUSTRY, APPLICATIONS COVERED BY SECTION 505(B)(2), at 4 (1999). 
 79.   21 U.S.C. § 355(j)(2)(C) (2012). 
 80.  See Abbreviated New Drug Application Regulations, 54 Fed. Reg. 28,872 
(proposed July 10, 1989). 
 81.  See Abbreviated New Drug Application Regulations, 57 Fed. Reg. 17,950 
(April 28, 1992). 
 82.  See id. at 17,951–52 (discussing the FDA’s decision to make suitability 
petitions publicly available). 
 83.  See 21 C.F.R. § 314.93(a)–(d) (2013). 
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disapprove a suitability petition within ninety days after sub-
mission,84 and when the FDA may withdraw approval of a suitability 
petition.85 
There are no binding rules governing the FDA’s procedures in 
processing ANDA suitability petitions. The FDA’s normal 
procedure has been to have a petition first go to the Office of 
Generic Drugs (OGD), which is responsible for preparing a 
synopsis of the petition and providing its views on appropriate 
resolution to the FDA’s Suitability Petition Committee. The 
committee either approves the action on the petition 
recommended by the OGD or refers the matter to other FDA 
components for further review. Once a decision is prepared and, if 
necessary, reviewed by the FDA’s office of chief counsel, the 
approval or denial is sent to the petitioner by the OGD.86 
From the enactment of the Hatch-Waxman Act until 2003, the 
FDA’s consideration of and action on ANDA suitability petitions, 
although slow, was not generally affected by other changes in the 
law. That changed with the December 3, 2003 enactment of the 
Pediatric Research Equity Act of 2003 (PREA).87 PREA amended 
the FDC Act to add new section 505B.88 It significantly affected the 
FDA’s previous ANDA suitability petition decisions and the 
Agency’s ability to approve future suitability petitions for certain 
proposed changes. 
PREA essentially codified the FDA’s 1998 “Pediatric Rule.”89 
Under the Pediatric Rule, in order to promote more 
comprehensive pediatric testing and labeling, the FDA required 
 
 84.  See id. § 314.93(e). 
 85.  See id. § 314.93(f) (“[The] FDA may withdraw approval of a petition if the 
[A]gency receives any information demonstrating that the petition no longer 
satisfies the conditions under paragraph (e) of this section.”). 
 86.  See generally CTR. FOR DRUG EVALUATION & RESEARCH, FOOD DRUG 
ADMIN., MAPP 5240.5 MANUAL OF POLICIES AND PROCEDURES: OFFICE OF GENERIC 
DRUGS ANDA SUITABILITY PETITIONS (2013), available at http://www.fda.gov 
/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco 
/CDER/ManualofPoliciesProcedures/UCM365676.pdf. 
 87.  Pub. L. No. 108-155, 117 Stat. 1936 (codified as amended at 21 U.S.C. 
§§ 284m, 355–355c (2012)). 
 88.  Id. § 2, 117 Stat. at 1936 (codified as amended at 21 U.S.C. § 355c). 
 89.  See Regulations Requiring Manufacturers to Assess the Safety and 
Effectiveness of New Drugs and Biological Products in Pediatric Patients, 63 Fed. 
Reg. 66,632 (Dec. 2, 1998) (codified at 21 C.F.R. §§ 201, 312, 314, 601); see also 
21 C.F.R. §§ 201.23, 314.55, 601.27 (1999). 
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manufacturers submitting certain applications to evaluate the safety 
and effectiveness of their products in pediatric populations, unless 
the requirement was waived or deferred by the FDA.90 The Pediatric 
Rule became effective on April 1, 1999, but was invalidated in 
October 2002 by the United States District Court for the District of 
Columbia as exceeding the FDA’s statutory authority under the 
FDC Act.91 Legislation was pursued that would enable the FDA to 
require pediatric studies for certain applicants, culminating in the 
enactment of PREA. 
Under PREA as initially enacted, Congress granted the FDA 
with the statutory authority to require pediatric studies in certain 
defined circumstances retroactive to April 1, 1999.92 Specifically, 
the statute states that an applicant “that submits . . . an application 
(or supplement to an application) . . . under section [505 of the 
FDC Act] for a new active ingredient, new indication, new dosage form, 
new dosing regimen, or new route of administration . . . shall submit 
with the application” the results of pediatric studies assessing “the 
safety and effectiveness of the drug . . . for the claimed indications 
in all relevant pediatric subpopulations; and . . . to support dosing 
and administration for each pediatric subpopulation for which the 
drug . . . is safe and effective,” unless the FDA defers or partially or 
fully waives this requirement.93 
An ANDA requiring an approved suitability petition for a 
change in the RLD in an active ingredient, route of administration, 
or dosage form triggers PREA because it is a type of application 
submitted under FDC Act section 505. The only change permitted 
 
 90.  See Kurt R. Karst, Comment, Pediatric Testing of Prescription Drugs: The Food 
and Drug Administration’s Carrot and Stick for the Pharmaceutical Industry, 49 AM. U. L. 
REV. 739, 754 (2000). 
 91.  Ass’n of Am. Physicians & Surgeons v. FDA, 226 F. Supp. 2d 204, 222 
(D.D.C. 2002). 
 92.  See Pediatric Research Equity Act, §§ 2, 4, 117 Stat. at 1936, 1942; see also 
Letter from Gary Buehler, Dir., Office of Generics, FDA Ctr. for Drug Evaluation 
& Research, to Richard S. Morey, Att’y, Kleinfeld, Kaplan & Becker (Feb. 11, 
2004), available at http://www.fda.gov/ohrms/dockets/dailys/04/June04/061004 
/04p-0262-cp00001-Tab-3-vol1.pdf (“PREA applies retroactively to all suitability 
petitions submitted on or after April 1, 1999, and affects suitability petitions 
already approved as well as those currently pending or not yet submitted.”). 
 93.  FDC Act § 505B(a)(1)–(4), 21 U.S.C. § 355c(a)(1)–(4) (2012) (emphasis 
added).  
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by a suitability petition that does not trigger PREA is a change in 
strength from the RLD.94 
FDC Act section 505(j)(2)(C)(i) requires that the FDA deny a 
suitability petition if “investigations must be conducted to show the 
safety and effectiveness of the drug or of any of its active 
ingredients, the route of administration, the dosage form, or 
strength which differ from the listed drug.” The requirement to 
conduct (or even a deferral from conducting) pediatric studies 
triggers the statutory requirement to deny a suitability petition. 
Thus, unless the FDA fully waives the PREA pediatric studies 
requirement, the Agency must deny a suitability petition that 
requests permission to submit an ANDA for a change in route of 
administration, dosage form, or active ingredient vis-à-vis the RLD. 
The FDA stated this interpretation as early as 2004,95 and later 
withdrew approval of 128 suitability petitions in accordance with 
PREA.96 
III. SLOTH: THE FDA’S ANDA SUITABILITY PETITION DECISION 
TRACK RECORD 
Over the thirty years that the FDA has reviewed and acted on 
ANDA suitability petitions, the Agency has fallen victim to one of 
the seven deadly sins: sloth. A review of nearly 1300 ANDA 
suitability petitions submitted to the FDA since the enactment of 
the Hatch-Waxman statutory provision creating them shows that 
the FDA has been largely unable to meet the mandatory statutory 
ninety-day deadline of approving or disapproving a petition, 
particularly in recent years, despite a decline in the number of 
petitions submitted to the FDA. 
The tables included in the appendix to this article are the 
culmination of this author’s review of myriad sources of 
 
 94.  See FDC Act § 505B(a)(1)(A), 21 U.S.C. § 355c(a)(1)(A) (listing as 
affected by PREA, a marketing application for approval of a “new active 
ingredient, new indication, new dosage form, new dosing regimen, or new route 
of administration”) 
 95.  See Letter from Gary Buehler, supra note 92 (“If the change proposed in 
an ANDA suitability petition does not qualify for a full waiver of the pediatric 
studies, the approval of that petition will be revoked because, under PREA, clinical 
studies are required to demonstrate the safety and or effectiveness of the 
change.”). 
 96.  See Withdrawal of Approval of 128 Suitability Petitions, 72 Fed. Reg. 8184 
(Feb. 23, 2007). 
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information showing citizen petitions submitted to the FDA 
between September 24, 1984, and December 31, 2013, and 
identified in such records as ANDA suitability petitions. Although 
the FDA posts a list of ANDA suitability petitions on the Agency’s 
website,97 that list is incomplete. The FDA’s list omits, for example, 
approved suitability petitions withdrawn as result of the enactment 
of PREA and any suitability petitions submitted before March 31, 
1999. In order to form a more complete account of the FDA’s 
record of acting on suitability petitions, the author’s analysis 
includes such petitions without regard to their ultimate withdrawal 
of approval as a result of PREA.98 
For each year from 1984 to 2013, the author tabulated the 
number of ANDA suitability petitions submitted to the FDA. Those 
results are shown in Table 1 in the appendix to this article. After 
tabulating the number of suitability petitions submitted to the FDA 
annually, the author examined for each year the number of 
petitions the FDA approved and denied, the number of petitions 
withdrawn by the petitioner before receiving a substantive response 
from the FDA, and the number of petitions that remain pending as 
of December 31, 2013. Those results are shown separately in Tables 
2–5, with Table 6 showing, in line graph format, the combined data 
in Tables 2–5. 
Next, the author calculated for each year cohort the average 
and median times for the FDA to respond to a petition by either 
approving or disapproving the petition, based on the date of 
petition submission to the FDA and the date of the Agency’s 
response. For this analysis, petitions withdrawn by the petitioner 
before an FDA approval or disapproval decision were excluded 
from the calculation. In addition, separate calculations were 
performed for each year cohort that both exclude and include 
 
 97.  See Suitability Petitions, FOOD & DRUG ADMIN., http://www.fda.gov/drugs 
/developmentapprovalprocess/howdrugsaredevelopedandapproved/approval 
applications/abbreviatednewdrugapplicationandagenerics/ucm120944.htm 
(last updated Feb. 5, 2014). 
 98.  Omitted from this analysis are sixteen ANDA suitability petitions 
submitted to the FDA prior to the September 24, 1984, enactment of the Hatch-
Waxman Act, when the FDA’s suitability petition regulations were in force, 
regardless of whether or not the FDA approved or disapproved such petitions after 
September 24, 1984. Because the FDA’s suitability petition regulations did not 
require the FDA to decide on such petitions within a defined period, there was no 
specific expectation at the time of submission that the FDA would approve or 
disapprove these petitions within ninety days.  
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suitability petitions pending an FDA approval or disapproval 
decision as of December 31, 2013. 
When including pending petitions, the number of days 
pending was calculated based on the day of petition submission to 
the FDA and as of December 31, 2013. Those results are shown in 
Tables 7–12, with Tables 9 and 12 comparing the average and 
median numbers of days to an FDA decision both where pending 
petitions are excluded and included, respectively. Because there 
are ANDA suitability petitions pending, an FDA decision as far back 
as 2001 (Table 6), excluding pending petitions yields actual annual 
average and median FDA decision timeframes, and that are 
significantly less than the possible annual average and median FDA 
decision timeframes calculated when such pending petitions are 
included. Ultimately, if such petitions are not withdrawn and are 
ruled on by the FDA, then their potentiality will be actualized. 
Each table appears, at first blush, to reflect a significant 
downward trend in recent years in the average and median times 
for the FDA to rule on a suitability petition, regardless of whether 
or not pending petitions are included or excluded from the 
analysis. The “trend” is somewhat illusory, however, for two related 
reasons. First, there are a large number of pending suitability 
petitions submitted to the FDA in recent years that the Agency has 
not yet approved or disapproved. Second, for purposes of our 
analysis, the author needed to institute a cutoff date of December 
31, 2013 that is artificial. As such, petitions submitted to the FDA in 
recent years but not yet ruled on have not “aged” to the extent that 
older petitions—whether or not yet ruled on by the FDA—have 
“aged.” If the FDA were to promptly approve or disapprove 
pending petitions submitted to the Agency in recent years, then 
there would, in fact, be a downward trend in average and median 
times. If, however, the FDA allows pending petitions submitted to 
the Agency in recent years to languish without a ruling, then the 
Agency’s actual decision timeframe will remain high. 
One trend that is not illusory is an upward trend in decision 
timeframes beginning around 2002 or 2003 and peaking around 
2007. The start of this trend generally coincides with the enactment 
of PREA, and may reflect additional time taken by the FDA’s OGD 
to rule on suitability petitions because of the need to consult other 
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FDA components on pediatric testing issues, such as the FDA’s 
Pediatric Review Committee (PeRC).99 
Finally, the author consolidates several of the tables above to 
show, in Tables 13 and 14, an overview of the numbers of petitions 
submitted, withdrawn, and acted on by the FDA vis-à-vis the average 
and median figures shown above (in line graph format), both 
including and excluding pending petitions. In order to show all of 
these data on a single table, the numbers showing average and 
median FDA response timeframes (both including and excluding 
pending suitability petitions) have been reduced by a factor of ten 
(i.e., 100 = 10). 
IV. LOSS OF FAITH: POSSIBLE REASONS FOR THE DECLINE IN THE 
POPULARITY OF THE PETITIONED ANDA 
Two trends in particular stand out when examining the tabular 
results presented in Part III of this article: (1) despite initial 
excitement, the generic drug industry’s interest in ANDA suitability 
petitions has waned, particularly in the past four years; and 
(2) despite some early success, the FDA has been unable to meet, 
on an annual basis for petitions submitted in each cohort year, the 
statutory ninety-day deadline for approving or disapproving ANDA 
suitability petitions. Indeed, as shown in Tables 15 and 16, adding 
linear trend lines to two of the tables from Part III above clearly 
shows the number of ANDA suitability petitions on the downswing 
and the FDA’s average and median response times (even excluding 
pending petitions) on the upswing. 
It is logical to conclude that the two trends are related. The 
longer it takes for the FDA to approve or disapprove an ANDA 
suitability petition, the less incentive there is for the generic drug 
industry to submit such petitions, because it is unknown if the FDA 
will rule on the petition in a reasonable timeframe so that a generic 
drug company can plan its development of a drug accordingly.100 
 
 99.  See generally 21 U.S.C. § 355d (2012) (establishing the PeRC). 
 100.  Curiously, no generic drug company has yet, to this author’s knowledge, 
challenged the FDA in court over the Agency’s unreasonable delay in ruling on an 
ANDA suitability petition. Nevertheless, there appears to be a basis for such a 
challenge under the Administrative Procedures Act (APA), 5 U.S.C. §§ 501–596 
(2012), alleging that the FDA failed to perform a nondiscretionary statutory duty 
to timely act upon an ANDA suitability petition within ninety days. Indeed, there is 
precedent for courts compelling the FDA to act on a mandatory obligation when 
plaintiffs have alleged unreasonable delay. In Sandoz, Inc. v. Leavitt, 427 F. Supp. 
23
Karst: Letting the Devil Ride: Thirty Years of ANDA Suitability Petition
Published by Mitchell Hamline Open Access, 2014
 
2014] ANDA SUITABILITY PETITIONS 1283 
In other words, the generic drug industry has lost faith in the 
ANDA suitability petition process.101 Part V of this article proposes 
how the FDA (or Congress) can redeem the faith of the generic 
drug industry in the suitability petition process; however, before 
moving on to that final topic, it bears noting that the glacial pace at 
which the FDA rules on suitability petitions is not the sole factor for 
the generic drug industry’s waning interest in submitting suitability 
petitions to the FDA. A couple of other factors are relevant. 
As discussed in Part II of this article,102 PREA significantly 
affected the FDA’s ability to approve suitability petitions seeking 
permission to submit an ANDA for a drug product that deviates 
from the RLD in dosage form, route of administration, and active 
ingredient in a combination drug product. As a result, fewer 
suitability petitions have been submitted to the FDA requesting 
permission for such changes. For example, of the twenty-three 
suitability petitions submitted to the FDA in 2011, eighteen of them 
requested permission to submit an ANDA for a new strength, while 
four requested permission for a new dosage form, and one for both 
a new strength and new dosage form. 
 
2d 29, 41 (D.D.C. 2006), the plaintiff successfully sued the FDA for not approving 
or disapproving its NDA in over 1000 days (over five times the statutory deadline 
of 180 days). In In re Barr Laboratories, Inc., 930 F.2d 72, 73 (D.C. Cir. 1991), the 
plaintiff sought a writ of mandamus compelling the FDA to either approve or 
disapprove twenty-three of Barr’s ANDAs, claiming that the FDA had repeatedly 
missed the statutory 180-day deadline. The court did not grant relief to the 
plaintiff, finding that granting the writ would only put Barr at the head of the 
queue and simply move all others back one space. See id. at 75. The court did, 
however, hold that the FDA’s compliance with the 180-day deadline was 
mandatory and not merely a policy recommendation. See id. at 76.  
 101.  Whether the FDA has also lost faith in the ANDA suitability petition 
process, because of a low “rate of return” on the investment needed to review and 
act on suitability petitions, is another factor that may affect the lengthy FDA 
decision process. That is, if the FDA is of the mindset that the Agency’s approval of 
suitability petitions is not resulting in the submission and approval of ANDAs 
based on those decisions, then there is a disincentive for the FDA to promptly 
review and rule on suitability petitions. Unfortunately, because specific 
information about ANDA submissions is maintained by the FDA as confidential 
information, it is impossible to gauge the success of the suitability petition process 
by virtue of the number of ANDA submissions made based on an approved 
suitability petition, as not all applications submitted to the FDA are approved. 
Although it might be possible to tabulate the number of petitioned ANDAs the 
FDA has ever approved, this author has not yet attempted to undertake that 
monumental task. 
 102.  See supra notes 89–96 and accompanying text. 
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Another factor that may affect the number of ANDA suitability 
petitions submitted to the FDA annually is the growing popularity 
of the section 505(b)(2) NDA as a route to obtain approval of a 
drug product that deviates in some respect from a brand-name 
drug approved under an NDA. A generic drug manufacturer may 
use the section 505(b)(2) NDA route as an alternative to 
submitting an ANDA subject to an approved suitability petition for 
each of the types of changes permitted via a suitability petition, as 
well as myriad other changes not permitted under the ANDA 
approval route.103 Indeed, when faced with the decision of either 
petitioning the FDA for permission to submit an ANDA, the 
submission of which may not occur for several years, or 
immediately submitting a section 505(b)(2) NDA to the FDA 
without having to first request, and then await, the Agency’s 
permission, companies may well choose the latter option. Although 
the submission of a section 505(b)(2) application is more costly 
than an ANDA submission,104 the FDA is almost certain to take an 
approval action on a section 505(b)(2) NDA before an ANDA,105 
 
 103.  See FOOD & DRUG ADMIN., supra note 78, at 4. 
 104.  Under the Prescription Drug User Fee Amendments of 2012 (PDUFA) of 
the Food and Drug Administration Safety and Innovation Act, Pub. L. No. 112-
144, tit. I, 126 Stat. 993, 996 (2012), the FDA is authorized to collect user fees for 
certain applications for approval of drug and biological products, on 
establishments where the products are manufactured, and on such products. The 
fee to submit a section 505(b)(2) application to the FDA in fiscal year 2014 that 
does not contain clinical data is $1,084,550. See Notice, Prescription Drug User Fee 
Rates for Fiscal Year 2014, 78 Fed. Reg. 46,980 (Aug. 2, 2013). Similarly, under the 
Generic Drug User Fee Amendments of 2012 (GDUFA), tit. III, 126 Stat. at 1008, 
the FDA is authorized to collect user fees for certain applications for approval of a 
generic drug, among other types of fees. The fiscal year 2014 ANDA fee is $63,860. 
See Notice, Generic Drug User Fee—Abbreviated New Drug Application, Prior 
Approval Supplement, Drug Master File, Final Dosage Form Facility, and Active 
Pharmaceutical Ingredient Facility Fee Rates for Fiscal Year 2014, 78 Fed. 
Reg. 46,977 (Aug. 2, 2013).  
 105.  Under the latest iteration of PDUFA, the FDA agreed to act on ninety 
percent of the NDAs typically submitted to the Agency within either ten months of 
the receipt date (standard applications) or within six months of the receipt date 
(priority applications). See Food & Drug Admin., PDUFA Reauthorization Performance 
Goals and Procedures Fiscal Years 2013 Through 2017, http://www.fda.gov/downloads 
/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM270412.pdf (last visited 
Apr. 28, 2014). Under GDUFA, the FDA has agreed to certain performance goals 
concerning ANDA approval actions; however, those goals do not go into effect 
until fiscal year 2015. See Food & Drug Admin., GDUFA Program Performance Goals 
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thereby allowing a company to earn a return on its investment 
quicker than if it had chosen the ANDA suitability petition route. 
A corollary to a company choosing to submit a section 
505(b)(2) NDA to the FDA instead of availing itself of the 
suitability petition route to ANDA submission and approval is that 
approval of a section 505(b)(2) NDA may be used to “short circuit” 
a generic drug sponsor’s plans to obtain approval of a petitioned 
ANDA for the same change covered by an approved section 
505(b)(2) NDA. First, the FDA will not approve a pending 
suitability petition for a change that describes an approved 
pharmaceutically equivalent drug product, because the suitability 
petition process is intended for a proposed “drug product which is 
not identical to a listed drug in route of administration, dosage 
form, and strength, or in which one active ingredient is substituted 
for one of the active ingredients in a listed combination drug.”106 
Second, the FDA has historically required a generic drug applicant 
with a pending ANDA subject to an approved suitability petition to 
change RLD and provide appropriate bioequivalence information 
once the Agency has approved an application for the drug product 
covered by the suitability petition.107 A change made to the statute 
by the 2003 MMA, however, precludes the sponsor of a pending 
ANDA from amending its application to change RLD.108 Instead, 
the FDA requires the submission of a new ANDA citing the 
appropriate RLD, containing sufficient information to demonstrate 
bioequivalence to that RLD, and certifications to any patents listed 
in the Orange Book for that RLD.109 
Finally, it should be noted that the FDA has limited resources, 
but an increasing amount of responsibility. This likely requires the 
FDA to choose which tasks and obligations should take precedence 
over others. With respect to ANDAs, the FDA has seen a near-
 
and Procedures, http://www.fda.gov/downloads/ForIndustry/UserFees/Generic 
DrugUserFees/UCM282505.pdf (last visited Apr. 28, 2014).  
 106.  21 C.F.R. § 314.93(b) (2013). 
 107.  See Letter from Janet Woodcock, Dir., Ctr. for Drug Evaluation Research, 
to Mark S. Aikman, Vice President, Regulatory Affairs and Quality Assurance, 
Osmotica Pharm. Corp. (Nov. 25, 2008) (quoting Letter from G. Buehler, Dir., 
Office of Generic Drugs, Food & Drug Admin., to Undisclosed Applicants 
Regarding ANDAs for Carboplatin Injection, 10 mg/mL (Aug. 12, 2004)), 
available at http://www.regulations.gov/#!documentDetail;D=FDA-2008-P-0329 
-0016. 
 108.  See FDC Act § 505(j)(2)(D)(i), 21 U.S.C. § 355(j)(2)(D)(i) (2012). 
 109.  See Letter from Janet Woodcock, supra note 107. 
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tripling of applications submitted to the Agency over the past 
decade, resulting in a significant backlog of applications. The 
“slippage” in reviewing and acting on suitability petitions and the 
increase in ANDA submissions and the backlog of pending 
applications are likely not coincidence.110 
V. REDEMPTION OF FAITH: THE FDA SHOULD IMPLEMENT 
PROCEDURES TO CONSISTENTLY MEET THE NINETY-DAY 
STATUTORY DEADLINE FOR ACTING ON ANDA SUITABILITY 
PETITIONS, OR CONGRESS SHOULD AMEND THE LAW WITH A 
MORE PRACTICAL DEADLINE 
Despite the FDA’s historical policy of sloth and lassitude in 
ruling on ANDA suitability petitions, leading to a loss of faith in the 
process itself, there is still hope that the FDA can redeem itself. But 
to do so, the FDA will need to make a concerted effort to promptly 
act on ANDA suitability petitions. Indeed, such an effort is already 
afoot at the FDA. In August 2013, the FDA published a Manual of 
Policies and Procedures (MaPP)111 establishing the policies and 
procedures for responding to suitability petitions, and reiterating 
that “[u]nder 21 CFR 314.93(e), the Agency will approve or deny 
the petition no later than 90 days after the petition is submitted.”112 
According to the MaPP: 
OGD’s goal is to respond to suitability petitions in an 
efficient and effective manner. To meet this goal, a 
number of parties within the Center for Drug Evaluation 
and Research (CDER) and throughout the Agency must 
work in a coordinated manner. OGD, the office primarily 
responsible for responding to suitability petitions, has 
developed procedures for enhancing communication 
among parties involved in addressing the request(s) in the 
suitability petitions.113 
Because the FDA’s MaPP became effective only relatively recently, 
in August 2013, it is not yet clear what effect (if any) it has had on 
speeding up the FDA’s review of new and long-pending ANDA 
suitability petitions. If, given the passage of time, the policies and 
procedures stated in the MaPP do not yield significant 
 
 110.  Indeed, the personnel in the FDA’s OGD tasked with reviewing ANDAs 
are the same personnel tasked with handling suitability petitions. 
 111.  CTR. FOR DRUG EVALUATION & RESEARCH, supra note 86. 
 112.  Id. at 1. 
 113.  Id. at 2. 
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improvements in meeting the statutory ninety-day deadline, then 
perhaps Congress should amend the statute to reset the deadline to 
one that is more practical for the FDA to meet. 
In other recent instances where Congress has required the 
FDA to respond to certain types of citizen petitions in 150 days, 
180 days, and 270 days, the FDA has been quite successful in 
meeting those statutory deadlines. In 2007, the FDC Act was 
amended to require that the FDA respond, within 180 days, to 
certain citizen petitions and petitions for stays of action that 
request that the FDA take any form of action related to a pending 
ANDA or section 505(b)(2) NDA.114 That 180-day deadline was 
reduced to 150 days in 2012.115 Of the 116 petitions submitted to 
the FDA through fiscal year 2012 subject to the 180-day or 150-day 
deadline, the FDA has missed that deadline only twice.116 
The FDC Act was also amended in 2012117 to require that the 
FDA respond within 270 days to citizen petitions requesting that 
the FDA determine whether a particular RLD was withdrawn from 
sale for reasons of safety or effectiveness.118 The FDA has thus far 
 
 114.  See FDC Act § 505(q), 21 U.S.C. § 355(q) (2012). This section of the law 
was added by section 914 of the Food and Drug Administration Amendments Act 
of 2007, Pub. L. No. 110-85, § 914, 121 Stat. 823, 953–57. 
 115.  See Food and Drug Administration Safety and Innovation Act, Pub. L. 
No. 112-144, § 1135, 126 Stat. 993, 1123 (2012). 
 116.  See FOOD & DRUG ADMIN., REPORT TO CONGRESS, FIFTH ANNUAL REPORT ON 
DELAYS IN APPROVALS OF APPLICATIONS RELATED TO CITIZEN PETITIONS AND PETITIONS 
FOR STAY OF AGENCY ACTION FOR FISCAL YEAR 2012, at 4 (2013), available at http:// 
www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsand
Tobacco/CDER/ReportsBudgets/UCM369780.pdf; see also Kurt R. Karst, FDA’s 
Fifth Annual Report to Congress on 505(q) Citizen Petitions: Something Old, Something 




 117.  See FDC Act § 505(w), 21 U.S.C. § 355(w). This section of the law was 
added by section 1134 of the Food and Drug Administration Safety and Innovation 
Act, Pub. L. No. 112-144, § 1134, 126 Stat. 993, 1123 (2012). 
 118.  The FDA may refuse to approve an ANDA if the Agency determines that 
the RLD was withdrawn from sale for reasons of safety or effectiveness. See FDC Act 
§ 505(j)(4)(I), 21 U.S.C. § 355(j)(4)(I). In addition, the FDA can withdraw (or 
suspend) approval of an ANDA if the RLD is withdrawn from sale for reasons of 
safety or effectiveness. See FDC Act § 505(j)(6), 21 U.S.C. § 355(j)(6). The FDA 
acknowledged in the preamble to the Agency’s July 1989 proposed regulations 
implementing the 1984 Hatch-Waxman Act that the law does not “specify 
procedures to be followed in determining whether a drug that is voluntarily 
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met that deadline for the relatively small number of petitions 
submitted pursuant to 21 C.F.R. § 314.161. 
Clearly, the FDA can meet a statutory deadline for responding 
to a citizen petition when the Agency wants to do so, and when the 
Agency has sufficient time to do so. Perhaps the ninety-day 
deadline for approving or disapproving an ANDA suitability 
petition is insufficient for the FDA to complete its analysis and 
compose a decision. There might also be a mindset at the FDA that 
once the ninety-day period is breached, there is less impetus for the 
FDA to promptly rule on a suitability petition. That is, there may be 
a mindset that “a miss is a miss no matter how close to, or far off of, 
the mark you are.” To address both of these issues, Congress 
should consider extending––perhaps as part of the next iteration of 
the Generic Drug User Fee Amendments of 2012 (GDUFA) that 
will be taken up in the coming years––the ninety-day response 
deadline to reflect deadlines that are more familiar to and 
attainable by the FDA, such as the 150-day, 180-day, or 270-day 
petition response deadlines imposed by Congress in recent years. 
An attainable deadline will give greater certainty to the ANDA 
suitability petition process, will reassure the generic drug industry 
that it is a viable and practical route to ANDA approval, and may 
lead to a renewed interest in submitting ANDA suitability 
petitions.119 
 
withdrawn from sale by its manufacturer is withdrawn for safety or effectiveness 
reasons.” Abbreviated New Drug Application Regulations, 54 Fed. Reg. 28,872, 
28,907 (proposed July 10, 1989). As such, the FDA took it upon itself to create 
such a procedure. The FDA’s interpretation of the Hatch-Waxman Act is 
embodied in the Agency’s regulations, which provide that “[a]ny person may 
petition under §§ 10.25(a) and 10.30 of this chapter for a determination whether 
a listed drug has been voluntarily withdrawn for safety or effectiveness reasons.” 
21 C.F.R. § 314.161(b) (2013). 
 119.  There are alternatives to amending the FDC Act’s ANDA suitability 
petition provisions with a more practical deadline. For example, Congress could 
abolish the suitability petition procedures because the section 505(b)(2) NDA 
pathway already provides a route to obtain approval of an application for the types 
of changes permitted in a suitability petition, and without the need to first obtain 
the FDA’s permission. Small generic drug companies that may use the suitability 
petition procedures might object to such a move because of the significant user 
fee payment that must accompany a section 505(b)(2) NDA submission (and 
annual product and establishment user fee payments), unless PDUFA is also 
amended to include a reduction or exemption from user fees. Congress could also 
amend the FDC Act to permit the submission of an ANDA for a petitioned change 
unless the FDA disapproves a petition within ninety days of submission. Such a 
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VI. CONCLUSION 
Despite initial popularity, interest in the ANDA suitability 
petition has waned in recent years. This is likely the result of a 
confluence of factors; however, the FDA’s inability to meet the 
statutory ninety-day deadline for approving or disapproving a 
suitability petition has resulted in a loss of faith in the petition 
process. The petitioned ANDA remains a viable route for many 
generic drug applicants to obtain approval of a drug product 
without having to conduct expensive and time-consuming clinical 
studies, but to renew trust and reinvigorate interest in the 
petitioned ANDA, change is necessary. Recently, the FDA indicated 
that it is committed to acting promptly on suitability petitions. If 
the FDA’s renewed interest in meeting the statutory ninety-day 
deadline is unsuccessful, then Congress should consider amending 
the FDC Act with a more practical deadline. 
  
 
change would effectively remove the condition precedent currently in the statute 
and create greater urgency for FDA to review and act on a suitability petition in a 
timely manner.  
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Table 6: ANDA Suitability Petition Approvals, Denials, 
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Table 7: Average Number of Days to FDA Decision (Approval or 
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Table 8: Median Number of Days to FDA Decision (Approval or 
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Table 9: Average and Median Number of Days to FDA Decision 
(Approval or Denial) by Year (1984–2013)— 
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Table 10: Average Number of Days to FDA Decision (Approval or 
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Table 11: Median Number of Days to FDA Decision (Approval or 
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Table 12: Average and Median Number of Days to FDA Decision 
(Approval or Denial) by Year (1984–2013)— 
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Table 13: ANDA Suitability Petition Submission & Action 
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Table 14: ANDA Suitability Petition Submission and Action by 
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Table 16: Average & Median Number of Days to FDA 
Decision (Approval or Denial) by Year (1984–2013)— 
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